A Phase 4 interventional study of Dobutamine in Heart Failure, sponsored by University of Aarhus. Suspended at 1 site in Denmark. Open to participants aged 19 Years to 90 Years. Per ClinicalTrials.gov, last updated 2013-08-07.
Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment
The use of dobutamine in postoperative hemodynamic treatment is widespread despite seemingly intact contraction of the heart. This study aims to elucidate the efficacy of low-dose dobutamine infusion in patients in the postoperative phase replacement of the aortic valve.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 10 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.
Browse Heart Failure studies →University of Aarhus is the lead sponsor of 1,274 studies on the registry; 183 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Drug: Dobutamine
90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
Cardiac output
Change in cardiac output (l/min) from initiation of study drug or placebo until 90 minutes of infusion.
Time frame: From 0 to 90 minutes after drug initiation
Mean pulmonary artery pressure
Changes in pulmonary artery pressure (mmHg) from start of study drug or placebo infusion until 90 minutes after the start.
Time frame: From 0 to 90 minutes after drug initiation.
Echocardiography
Echocardiographic measures of systolic and diastolic heart function.
Time frame: From 0 minutes to 90 minutes after drug initiation
Changes in mixed venous saturation
Changes in mixed venous saturation (in per cent) from baseline until the end of dobutrex or placebo infusion.
Time frame: From 0 minutes to 90 minutes after drug initiation
norepinephrine requirement
The amount of norepinephrinem(mg) required to maintain adequate systemic blood pressure during the infusion period of dobutrex and placebo
Time frame: From 0 minutes to 90 minutes after drug initiation
Central venous pressure
Changes in CVP from baseline until 90 minutes of study drug or placebo infusion.
Time frame: From 0 minutes to 90 minutes after drug initiation
This study is suspended, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Aarhus